Bank of Nova Scotia vs Medpace Holdings Inc — how do they compare? Bank of Nova Scotia trades at $90.21 (market cap $108.32B), while Medpace Holdings Inc trades at $599.46 (market cap $16.90B). The key difference: Bank of Nova Scotia is far larger — about 6.4× Medpace Holdings Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| BNS | MEDP | |
|---|---|---|
Market Cap | $108.32B | $16.90B |
Sector | Financials | Technology |
52-Week High | $90.29 | $620.59 |
52-Week Low | $56.41 | $393.42 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $16.52B |
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $89.92, up 1.54% with a bullish technical outlook supported by moving averages. The company demonstrates consistent earnings growth, beating estimates for three consecutive quarters with Q2 2026 expected at $1.53 EPS. Recent acquisition of MapleMark Bank and dividend increase to $1.14 highlight strategic growth initiatives. Valuation metrics show a P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a favorable investment case with analyst consensus leaning bullish (53% buy ratings) and technical indicators supporting upward momentum. Key opportunities include dividend growth, international expansion, and improving ROE at 11.87%. Risks include macroeconomic sensitivity, declining profit margins from 31.47% in 2022 to 20.99% in 2025, and elevated debt levels with $194.31 billion long-term obligations.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →